LIVIVO - Search results -

Search results

Result 1 - 10 of total 31

Search options

Article: Comprehensive 3DCRT Hypofractionated Radiotherapy Schedule for Localized Prostate Adenocarcinoma in the Era of IMRT: Dosimetric and Endoscopic Analysis.

Kougioumtzopoulou, Andromachi / Syrigos, Nick / Zygogianni, Anna / Georgakopoulos, Ioannis / Platoni, Kalliopi / Patatoukas, George / Tzannis, Kimon / Bamias, Aristotelis / Kelekis, Nikolaos / Kouloulias, Vasileios

Cancers

2024 Volume 16, Issue 6

Abstract: Background: ...

Abstract	Background:
Language	English
Publishing date	2024-03-18
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2527080-1
ISSN	2072-6694
ISSN	2072-6694
DOI	10.3390/cancers16061192
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Fungal Infections in the ICU during the COVID-19 Era: Descriptive and Comparative Analysis of 178 Patients.

Koukaki, Evangelia / Rovina, Nikoletta / Tzannis, Kimon / Sotiropoulou, Zoi / Loverdos, Konstantinos / Koutsoukou, Antonia / Dimopoulos, George

Journal of fungi (Basel, Switzerland)

2022 Volume 8, Issue 8

Abstract: Background: COVID-19-associated fungal infections seem to be a concerning issue. The aim of this study was to assess the incidence of fungal infections, the possible risk factors, and their effect on outcomes of critically ill patients with COVID-19.: ...

Abstract	Background: COVID-19-associated fungal infections seem to be a concerning issue. The aim of this study was to assess the incidence of fungal infections, the possible risk factors, and their effect on outcomes of critically ill patients with COVID-19. Methods: A retrospective observational study was conducted in the COVID-19 ICU of the First Respiratory Department of National and Kapodistrian University of Athens in Sotiria Chest Diseases Hospital between 27 August 2020 and 10 November 2021. Results: Here, 178 patients were included in the study. Nineteen patients (10.7%) developed fungal infection, of which five had COVID-19 associated candidemia, thirteen had COVID-19 associated pulmonary aspergillosis, and one had both. Patients with fungal infection were younger, had a lower Charlson Comorbidity Index, and had a lower PaO Conclusions: Fungal infections seem to have a high incidence in COVID-19 critically ill patients and specific risk factors are identified. However, fungal infections do not seem to burden on mortality.
Language	English
Publishing date	2022-08-21
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2784229-0
ISSN	2309-608X ; 2309-608X
ISSN (online)	2309-608X
ISSN	2309-608X
DOI	10.3390/jof8080881
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors.

Bamias, Aristotelis / Merseburger, Axel / Loriot, Yohann / James, Nicholas / Choy, Ernest / Castellano, Daniel / Lopez-Rios, F / Calabrò, Fabio / Kramer, Mario / de Velasco, Guillermo / Zakopoulou, Roubini / Tzannis, Kimon / Sternberg, Cora N

Journal for immunotherapy of cancer

2023 Volume 11, Issue 1

Abstract: Background: Bellmunt Risk Score, based on Eastern Cooperative Oncology Group (ECOG) performance status (PS), hemoglobin levels and presence of liver metastases, is the most established prognostic algorithm for patients with advanced urothelial cancer ( ... ...

Abstract	Background: Bellmunt Risk Score, based on Eastern Cooperative Oncology Group (ECOG) performance status (PS), hemoglobin levels and presence of liver metastases, is the most established prognostic algorithm for patients with advanced urothelial cancer (aUC) progressing after platinum-based chemotherapy. Nevertheless, existing algorithms may not be sufficient following the introduction of immunotherapy. Our aim was to develop an improved prognostic model in patients receiving second-line atezolizumab for aUC. Methods: Patients with aUC progressing after cisplatin/carboplatin-based chemotherapy and enrolled in the prospective, single-arm, phase IIIb SAUL study were included in this analysis. Patients were treated with 3-weekly atezolizumab 1200 mg intravenously. The development and internal validation of a prognostic model for overall survival (OS) was performed using Cox regression analyses, bootstrapping methods and calibration. Results: In 936 patients, ECOG PS, alkaline phosphatase, hemoglobin, neutrophil-to-lymphocyte ratio, liver metastases, bone metastases and time from last chemotherapy were identified as independent prognostic factors. In a 4-tier model, median OS for patients with 0-1, 2, 3-4 and 5-7 risk factors was 18.6, 10.4, 4.8 and 2.1 months, respectively. Compared with Bellmunt Risk Score, this model provided enhanced prognostic separation, with a c-index of 0.725 vs 0.685 and increment in c-statistic of 0.04 (p<0.001). Inclusion of PD-L1 expression did not improve the model. Conclusions: We developed and internally validated a prognostic model for patients with aUC receiving postplatinum immunotherapy. This model represents an improvement over the Bellmunt algorithm and could aid selection of patients with aUC for second-line immunotherapy. Trial registration number: NCT02928406.
MeSH term(s)	Humans ; Prognosis ; Carcinoma, Transitional Cell/drug therapy ; Immune Checkpoint Inhibitors/therapeutic use ; Urinary Bladder Neoplasms/drug therapy ; Prospective Studies ; Urologic Neoplasms ; Hemoglobins/therapeutic use
Chemical Substances	Immune Checkpoint Inhibitors ; Hemoglobins
Language	English
Publishing date	2023-01-07
Publishing country	England
Document type	Clinical Trial, Phase III ; Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2719863-7
ISSN	2051-1426 ; 2051-1426
ISSN (online)	2051-1426
ISSN	2051-1426
DOI	10.1136/jitc-2022-005977
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Management of stent-related symptoms with the use of α-blockers: A meta-analysis.

Deliveliotis, Konstantinos / Papatsoris, Athanasios G / Skolarikos, Andreas / Mitsogiannis, Iraklis / Tzannis, Kimon / Dellis, Athanasios E

Arab journal of urology

2019 Volume 18, Issue 1, Page(s) 14–21

Abstract: ... ...

Abstract	Objectives
Language	English
Publishing date	2019-11-14
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	2631788-6
ISSN	2090-598X
ISSN	2090-598X
DOI	10.1080/2090598X.2019.1690824
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Clinical presentation and outcomes of chronic dialysis patients with COVID-19: A single center experience from Greece.

Bacharaki, Dimitra / Karagiannis, Minas / Sardeli, Aggeliki / Giannakopoulos, Panagiotis / Tziolos, Nikolaos Renatos / Zoi, Vasiliki / Piliouras, Nikitas / Arkoudis, Nikolaos-Achilleas / Oikonomopoulos, Nikolaos / Tzannis, Kimon / Kavatha, Dimitra / Antoniadou, Anastasia / Vlahakos, Demetrios / Lionaki, Sophia

World journal of nephrology

2022 Volume 11, Issue 2, Page(s) 58–72

Abstract: Background: Coronavirus disease 2019 (COVID-19) is still a menacing pandemic, especially in vulnerable patients. Morbidity and mortality from COVID-19 in maintenance hemodialysis (MHD) patients are considered worse than those in the general population, ... ...

Abstract	Background: Coronavirus disease 2019 (COVID-19) is still a menacing pandemic, especially in vulnerable patients. Morbidity and mortality from COVID-19 in maintenance hemodialysis (MHD) patients are considered worse than those in the general population, but vary across continents and countries in Europe. Aim: To describe the clinical course and outcomes of hospitalized MHD patients with COVID-19 in a retrospective observational single center study in Greece. Methods: We correlated clinical, laboratory, and radiological data with the clinical outcomes of MHD patients hospitalized with COVID-19 during the pandemic. The diagnosis was confirmed by real-time polymerase chain reaction. Outcome was determined as survivors Results: We studied 32 patients (17 males), with a median age of 75.5 (IQR: 58.5-82) years old. Of those, 12 were diagnosed upon screening and 20 with related symptoms. According to the World Health Organization (WHO) score, the severity on admission was mild disease in 16, moderate in 13, and severe in 3 cases. Chest computed tomography (CT) showed 1-10% infiltrates in 24 patients. Thirteen "progressors" were recorded among included patients. The case fatality rate was 5/32 (15.6%). Three deaths occurred among "progressors" and two in "non-progressors", irrespective of co-morbidities and gender. Predictors of mortality on admission included frailty index, chest CT findings, WHO severity score, and thereafter the increasing values of serum LDH and D-dimers and decreasing serum albumin. Predictors of becoming a "progressor" included increasing number of neutrophils and neutrophils/lymphocytes ratio. Conclusion: Patients on MHD seem to be at higher risk of COVID-19 mortality, distinct from the general population. Certain laboratory parameters on admission and during follow-up may be helpful in risk stratification and management of patients.
Language	English
Publishing date	2022-03-19
Publishing country	United States
Document type	Journal Article
ISSN	2220-6124
ISSN	2220-6124
DOI	10.5527/wjn.v11.i2.58
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- Full text online
- Order with fees

Article: Acute Kidney Injury Predictors and Outcomes after Cardiac Surgery in Children with Congenital Heart Disease: An Observational Cohort Study.

Kourelis, Georgios / Kanakis, Meletios / Samanidis, George / Tzannis, Kimon / Bobos, Dimitrios / Kousi, Theofili / Apostolopoulou, Sotiria / Kakava, Felicia / Kyriakoulis, Konstantinos / Bounta, Stavroula / Rammos, Spyridon / Papagiannis, John / Giannopoulos, Nickolas / Orfanos, Stylianos E / Dimopoulos, George

Diagnostics (Basel, Switzerland)

2022 Volume 12, Issue 10

Abstract: Acute Kidney Injury (AKI) commonly complicates cardiac surgery in children with congenital heart disease (CHD). In this study we assessed incidence, risk factors, and outcomes of postoperative AKI, while testing the hypothesis that, depending on the ... ...

Abstract	Acute Kidney Injury (AKI) commonly complicates cardiac surgery in children with congenital heart disease (CHD). In this study we assessed incidence, risk factors, and outcomes of postoperative AKI, while testing the hypothesis that, depending on the underlying diagnosis, there would be significant differences in AKI incidence among different diagnostic groups. We conducted an observational cohort study of children with CHD undergoing cardiac surgery in a single tertiary center between January 2019 and August 2021 (n = 362). Kidney Disease Improving Global Outcome (KDIGO) criteria were used to determine the incidence of postoperative AKI. Diagnosis was incorporated into multivariate models using an anatomic-based CHD classification system. Overall survival was estimated using Kaplan−Meier curves. Log-rank test and adjusted Cox proportional hazard modelling were used to test for differences in survival distributions and determine AKI effect on survival function, respectively. AKI occurred in 70 (19.3%), with 21.4% in-hospital mortality for AKI group. Younger age, lower weight, longer cardiopulmonary bypass time, preoperative mechanical ventilation and diagnostic category were associated with postoperative AKI. Resolution rate was 92.7% prior to hospital discharge for survivors. AKI was associated with longer duration of mechanical ventilation, ICU and hospital length of stay. AKI patients had significantly higher probability of all-cause mortality postoperatively when compared to the non-AKI group (log-rank test, p < 0.001). Adjusted hazard ratio for AKI versus non-AKI group was 11.08 (95% CI 2.45−50.01; p = 0.002). Diagnostic category was associated with cardiac surgery-related AKI in children with CHD, a finding supporting the development of lesion specific models for risk stratification. Postoperative AKI had detrimental impact on clinical outcomes and was associated with decreased survival to hospital discharge.
Language	English
Publishing date	2022-10-02
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2662336-5
ISSN	2075-4418
ISSN	2075-4418
DOI	10.3390/diagnostics12102397
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Lower serum magnesium is a predictor of left ventricular hypertrophy in patients on dialysis.

Balafa, Olga / Dounousi, Evangelia / Giannikouris, Ioannis / Petrakis, Ioannis / Georgoulidou, Anastasia / Karassavidou, Despina / Kokalis, Apostolos / Stauroulopoulos, Aristeidis / Theodoridis, Marios / Oikonomidis, Ignatios / Triantafyllis, Georgios / Tsotsorou, Ourania / Tzannis, Kimon / Bacharaki, Dimitra

International urology and nephrology

2022 Volume 55, Issue 4, Page(s) 1015–1023

Abstract: Purpose: Left ventricular hypertrophy (LVH) represents one of the main risk factors for cardiovascular mortality in dialysis patients. Low serum magnesium Mg is related with increased mortality in general and dialysis population. Aim of our study was to ...

Abstract	Purpose: Left ventricular hypertrophy (LVH) represents one of the main risk factors for cardiovascular mortality in dialysis patients. Low serum magnesium Mg is related with increased mortality in general and dialysis population. Aim of our study was to evaluate the association of Mg with LVH and cardiac geometry in dialysis patients. Methods: Hemodialysis (HD) and peritoneal dialysis (PD) patients from nine nephrology departments were included. Echocardiographic LVH was defined by LV mass index > 95 g/m Results: 133 patients (68 HD, 65 PD) with a median age of 63 years (IQR 52-74) were studied. Mg correlated positively with creatinine, HDL and negatively with CRP levels and BMI. There were no significant differences in Mg between the modality groups. 80 patients presented LVH (43 HD and 37 PD patients). Patients with LVH were older (median age 68 vs 55 years, p < 0.001), with higher BMI (median 26.9 vs 24.7 kg/m Conclusion: Low serum magnesium levels seem to be an independent factor for LVH in hemodialysis and peritoneal dialysis patients.
MeSH term(s)	Male ; Humans ; Female ; Middle Aged ; Aged ; Renal Dialysis/adverse effects ; Magnesium ; Hypertrophy, Left Ventricular/complications ; Peritoneal Dialysis/adverse effects ; Echocardiography
Chemical Substances	Magnesium (I38ZP9992A)
Language	English
Publishing date	2022-10-24
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	204048-7
ISSN	1573-2584 ; 0301-1623 ; 0042-1162
ISSN (online)	1573-2584
ISSN	0301-1623 ; 0042-1162
DOI	10.1007/s11255-022-03391-2
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 733: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Vinflunine in the treatment of relapsed metastatic urothelial cancer: A systematic review and meta-analysis of real-world series.

Bamias, Aristotelis / Hegele, Axel / Medioni, Jacques / Castellano, Daniel / Doni, Laura / Passalacqua, Rodolfo / Zagouri, Flora / Tzannis, Kimon / Hussain, Syed / Ullen, Anders

Critical reviews in oncology/hematology

2019 Volume 140, Page(s) 80–87

Abstract: Background: Vinflunine (VFL) is approved in Europe as second-line treatment of metastatic urothelial cancer after failure of platinum-containing therapy. We performed a systematic review and meta-analysis of real-world data (RWD) to assess utilization, ... ...

Abstract	Background: Vinflunine (VFL) is approved in Europe as second-line treatment of metastatic urothelial cancer after failure of platinum-containing therapy. We performed a systematic review and meta-analysis of real-world data (RWD) to assess utilization, efficacy and safety of VFL. Methods: We performed a MEDLINE search for the period of 1/1/2000-31/8/2017. Full-length articles providing post-marketing RWD on VFL in patients failing previous chemotherapy were eligible. Interventional clinical trials were excluded. Results: Ten studies with 797 patients were identified. According to pooled REs analysis, overall response rate was 19%, most frequent, all-grade toxicities were fatigue (41%), constipation (39%), nausea/vomiting (25%), and most prevalent Grade 3-4 toxicities were neutropenia (13%), anaemia (9%), fatigue (8%). Median OS was comparable to results reported in recent randomized studies. Conclusion: Our findings confirm the efficacy and safety of VFL in an unselected population and support the use of VFL in the changing treatment paradigm of relapsed mUC.
MeSH term(s)	Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Constipation/chemically induced ; Europe ; Fatigue/chemically induced ; Female ; Humans ; Male ; Middle Aged ; Nausea/chemically induced ; Neoplasm Metastasis ; Platinum Compounds/therapeutic use ; Recurrence ; Treatment Outcome ; Urologic Neoplasms/drug therapy ; Urologic Neoplasms/pathology ; Vinblastine/adverse effects ; Vinblastine/analogs & derivatives ; Vinblastine/therapeutic use ; Vomiting/chemically induced
Chemical Substances	Platinum Compounds ; vinflunine (5BF646324K) ; Vinblastine (5V9KLZ54CY)
Language	English
Publishing date	2019-05-21
Publishing country	Netherlands
Document type	Journal Article ; Meta-Analysis ; Systematic Review
ZDB-ID	605680-5
ISSN	1879-0461 ; 0737-9587 ; 1040-8428
ISSN (online)	1879-0461
ISSN	0737-9587 ; 1040-8428
DOI	10.1016/j.critrevonc.2019.05.006
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1931: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Outcomes from treatment of metastatic renal-cell carcinoma following failure of first-line anti-VEGF/VEGFR therapy: real-life evidence on the change of the treatment paradigm.

Bamias, Aristotelis / Zakopoulou, Roubini / Tzannis, Kimon / Sakellakis, Minas / Koutsoukos, Konstantinos / Kyriazoglou, Anastasios / Panagiotou, Aikaterini / Armylagos, Stylianos / Rokas, Konstantinos / Gotzias, Dimitrios / Boulouta, Anna / Bozionelou, Vassiliki / Stravodimos, Konstantinos / Varkarakis, Ioannis / Mavroudis, Dimitrios / Dimopoulos, Meletios-Athanasios

Anti-cancer drugs

2022 Volume 34, Issue 3, Page(s) 413–421

Abstract: Recently approved agents for post-vascular endothelial growth factor/post-vascular endothelial growth factor receptor (VEGF/VEGFR) inhibitors treatment of metastatic renal-cell carcinomas (mRCC), such as axitinib, nivolumab, and cabozantinib were shown ... ...

Abstract	Recently approved agents for post-vascular endothelial growth factor/post-vascular endothelial growth factor receptor (VEGF/VEGFR) inhibitors treatment of metastatic renal-cell carcinomas (mRCC), such as axitinib, nivolumab, and cabozantinib were shown to improve prognosis and substituted everolimus in this setting. We studied practice patterns, efficacy, and tolerability of these agents in a real-world series of Greek patients. We included patients with mRCC who received everolimus, axitinib, or nivolumab after progression on first-line anti-VEGF/VEGFRs therapy. Patients were stratified into three groups. Group A received nivolumab with or without cabozantinib at some point in their disease. Group B received axitinib but without nivolumab or cabozantinib. Group C received only everolimus among the four approved agents. Overall, 131 patients were included in the analysis. Everolimus and nivolumab were mainly used in the second line, while axitinib and cabozantinib were mostly used in the third and fourth lines. Median overall survival (OS) from first-line initiation was 8.7 [95% confidence interval (CI), 4-not reached], 3.6 (95% CI, 2-6), and 2.1 years (95% CI, 1.4-2.6) for Group A, B, and C, respectively ( P < 0.001). Median OS from the initiation of second-line therapy was 3.5, 2.7, and 1.3 years, respectively ( P < 0.001). There was no impact of first-line agent or treatment timing on survival. International Metastatic Renal Cell Carcinoma Database Consortium risk stratification was associated with OS. Toxicities observed were within expected frequencies. Grade ≥3 events were rare. Adoption of modern standards in everyday treatment of mRCC results in prolongation of survival. Real-world datasets are the new landmarks of survival for future research.
MeSH term(s)	Humans ; Antineoplastic Agents/therapeutic use ; Axitinib/therapeutic use ; Carcinoma, Renal Cell/drug therapy ; Everolimus/therapeutic use ; Kidney Neoplasms/drug therapy ; Nivolumab/therapeutic use ; Vascular Endothelial Growth Factor A
Chemical Substances	Antineoplastic Agents ; Axitinib (C9LVQ0YUXG) ; cabozantinib (1C39JW444G) ; Everolimus (9HW64Q8G6G) ; Nivolumab (31YO63LBSN) ; Vascular Endothelial Growth Factor A
Language	English
Publishing date	2022-11-16
Publishing country	England
Document type	Clinical Trial ; Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	1065301-6
ISSN	1473-5741 ; 0959-4973
ISSN (online)	1473-5741
ISSN	0959-4973
DOI	10.1097/CAD.0000000000001420
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 3125: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Lymphocytic infiltration and Chemotherapy Response Score as prognostic markers in ovarian cancer patients treated with Neoadjuvant chemotherapy.

Liontos, Michalis / Sotiropoulou, Maria / Kaparelou, Maria / Tzannis, Kimon / Tsironis, George / Kyriazoglou, Anastasios / Tsiara, Anna / Zakopoulou, Roubini / Koutsoukos, Konstantinos / Zagouri, Flora / Thomakos, Nikolaos / Haidopoulos, Dimitrios / Rodolakis, Alexandros / Dimopoulos, Meletios A / Bamias, Aristotelis

Gynecologic oncology

2020 Volume 157, Issue 3, Page(s) 599–605

Abstract: Neoadjuvant Chemotherapy (NACT) followed by Interval Debulking Surgery (IDS) is an accepted frontline treatment in patients with advanced Epithelial Ovarian Cancer (EOC). Histopathologic assessment of tumor post NACT may provide a surrogate for response ... ...

Abstract	Neoadjuvant Chemotherapy (NACT) followed by Interval Debulking Surgery (IDS) is an accepted frontline treatment in patients with advanced Epithelial Ovarian Cancer (EOC). Histopathologic assessment of tumor post NACT may provide a surrogate for response to treatment. The present study aims to characterize the pathological response and to examine its prognostic significance in these patients. Medical records of women with EOC treated in our institution from 2011 to 2016 were retrospectively identified. IDS specimens were reviewed by study pathologist and Chemotherapy Response Score (CRS), lymphocytic infiltration, necrosis and mitosis were assessed. 55 patients with EOC treated with NACT were identified and 48 had complete clinical and pathological data. Median age was 63 years. CRS assessed at omentum predicted PFS when adjusted for age, stage, debulking status (complete, optimal, suboptimal) and post IDS bevacizumab administration (mPFS CRS 1 vs 2 vs 3: 10.3-14-18.7 months 95% CI [7.4-15.7], [12.2-22.9], [13.5-31.3]). Presence of lymphocytic infiltration was associated with improved OS (log-rank test P = 0.015). Post IDS bevacizumab was associated with shorter PFS in patients with lymphocytic infiltration. BRCA status was known for 25 patients and presence of BRCA1/2 mutations was strongly correlated with lymphocytic infiltration (P = 0.011) but not CRS omentum (P = 0.926). Our study confirms the predictive value of CRS in EOC patients treated with NACT and IDS, but also demonstrates the prognostic significance of lymphocytic infiltration as well as its possible interaction with bevacizumab treatment.
MeSH term(s)	Carcinoma, Ovarian Epithelial/blood ; Carcinoma, Ovarian Epithelial/drug therapy ; Carcinoma, Ovarian Epithelial/pathology ; Female ; Humans ; Lymphocytes/metabolism ; Middle Aged ; Neoadjuvant Therapy ; Prognosis
Language	English
Publishing date	2020-03-12
Publishing country	United States
Document type	Journal Article
ZDB-ID	801461-9
ISSN	1095-6859 ; 0090-8258
ISSN (online)	1095-6859
ISSN	0090-8258
DOI	10.1016/j.ygyno.2020.03.008
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 885: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito